玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性

Treatment of Wet Age-related Macular Degeneration with Vitreous Cavity Injection of Lucentis

目的:观察玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性(w AMD)的效果。方法:w AMD患者共38例(38只眼),采用玻璃体腔注射雷珠单抗注射,1次/月,共注射3次;观察注射前、注射后2周、1月、3月的最佳矫正视力(BCVA)以及黄斑中心凹厚度(CFT),同时观察患者眼压、炎症、前房积血、视网膜出血、白内障等术后不良反应及并发症,分析玻璃体腔注射雷珠单抗治疗前、后的情况。结果:治疗后2周、1月及3月BCVA均高于治疗前,并呈升高趋势,而CFT均低于治疗前,并呈下降趋势,差异有统计学意义(P<0.05);无眼内炎、视网膜脱离等严重不良反应及并发症发生。结论:玻璃体腔注射雷珠单抗治疗w AMD起效快疗效显著、副作用小。

Objective： To investigate the curative efficacy of vitreous cavity injection of monoclonal antibody （lucentis） on wet age- related macular degeneration （wAMD）. Method： A total of 38 pa- tients with wAMD were given lucentis in vitreous cavity, best corrected visual acuity （BCVA） and macular central foveal thickness （CFT） were observed before operation, two weeks, one month and three months after operation; postoperative adverse reactions and complications such as high intraocular pressure, inflammation, anterior chamber hemorrhage, retinal hemorrhage, cataracts were detected ; curative effect was analyzed. Results：Two weeks, 1 month and 3 months after treatment, BCVA was higher than that before treatment, and showed rising trend, while CFF was lower than that before treat- ment, and showed descending trend, the differences were statistically significant （ P 〈 0.05 ）. There was no serious adverse reaction and complication. Conclusion： Vitreous cavity injection of lucentis shows obvious curative effects and few adverse reactions.